9月24日，益方生物盘中上涨2.05%，截至10:09，报33.39元/股，成交1.20亿元，换手率0.88%，总市值 193.10亿元。 资金流向方面，主力资金净流出82.25万元，特大单买入316.54万元，占比2.64%，卖出318.33万元，占 比2.66%；大单买入1941.58万元，占比16.20%，卖出2022.04万元，占比16.87%。 益方生物今年以来股价涨151.05%，近5个交易日跌3.86%，近20日跌13.39%，近60日涨3.37%。 今年以来益方生物已经3次登上龙虎榜，最近一次登上龙虎榜为7月11日，当日龙虎榜净买入6887.06万 元；买入总计4.80亿元 ，占总成交额比44.57%；卖出总计4.11亿元 ，占总成交额比38.17%。 益方生物所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：创新药、抗癌药物、抗 癌治癌、年度强势、中盘等。 资料显示，益方生物科技(上海)股份有限公司位于中国(上海)自由贸易试验区李冰路67弄4号210室，成 立日期2013年1月11日，上市日期2022年7月25日，公司主营业务涉及创新药物的研发、生产和销售。主 营业务收入构成为 ...

Company Overview - Sichuan Kelun Pharmaceutical Co., Ltd. is located in Chengdu, Sichuan Province, established on May 29, 2002, and listed on June 3, 2010. The company specializes in the development, production, and sales of large-volume parenteral solutions [1][2] - The main business revenue composition includes: non-infusion products 48.37%, infusion products 41.28%, R&D projects 7.01%, and others 3.33% [1] Financial Performance - For the first half of 2025, Kelun Pharmaceutical achieved operating revenue of 9.083 billion yuan, a year-on-year decrease of 23.20%. The net profit attributable to shareholders was 1.001 billion yuan, down 44.41% year-on-year [2] - Since its A-share listing, the company has distributed a total of 6.697 billion yuan in dividends, with 3.386 billion yuan distributed in the last three years [3] Stock Market Activity - On September 24, Kelun Pharmaceutical's stock price increased by 2.00%, reaching 37.69 yuan per share, with a trading volume of 1.05 billion yuan and a turnover rate of 0.22%. The total market capitalization is 60.231 billion yuan [1] - Year-to-date, the stock price has risen by 28.07%, with a 2.03% increase over the last five trading days, 2.14% over the last twenty days, and 6.14% over the last sixty days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on April 30, where the net buying amount was 31.8792 million yuan [1] Shareholder Structure - As of June 30, 2025, the number of shareholders is 34,200, an increase of 2.55% from the previous period. The average circulating shares per person decreased by 2.49% to 38,138 shares [2] - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3]

Group 1 - The stock price of Lizhu Group fell by 2.01% on September 23, reaching 37.95 CNY per share, with a trading volume of 1.58 billion CNY and a turnover rate of 0.71%, resulting in a total market capitalization of 34.31 billion CNY [1] - Year-to-date, Lizhu Group's stock price has increased by 2.79%, but it has decreased by 5.88% in the last five trading days and by 9.15% in the last 20 days, while it has risen by 3.83% over the last 60 days [1] - As of June 30, 2025, Lizhu Group's revenue was 6.272 billion CNY, a year-on-year decrease of 0.17%, while the net profit attributable to shareholders was 1.281 billion CNY, reflecting a year-on-year increase of 9.40% [2] Group 2 - Lizhu Group's main business revenue composition includes chemical preparations (52.14%), APIs and intermediates (26.49%), traditional Chinese medicine preparations (12.75%), diagnostic reagents and equipment (5.97%), and biological products (1.51%) [2] - The company has distributed a total of 10.523 billion CNY in dividends since its A-share listing, with 3.721 billion CNY distributed in the last three years [3] - As of June 30, 2025, the number of shareholders in Lizhu Group was 46,400, a decrease of 11.30% from the previous period, while the average circulating shares per person increased by 12.71% to 12,581 shares [2]

诺诚健华今年以来股价涨119.22%，近5个交易日跌1.43%，近20日跌6.85%，近60日涨4.26%。 机构持仓方面，截止2025年6月30日，诺诚健华十大流通股东中，中欧医疗健康混合A（003095）位居 第六大流通股东，持股1304.78万股，相比上期增加398.07万股。富国精准医疗灵活配置混合A （005176）位居第七大流通股东，持股1258.20万股，持股数量较上期不变。鹏华医药科技股票A （001230）位居第八大流通股东，持股1020.21万股，相比上期减少501.14万股。易方达医疗保健行业混 合A（110023）位居第九大流通股东，持股918.57万股，为新进股东。汇添富创新医药混合A （006113）位居第十大流通股东，持股760.38万股，为新进股东。兴全合润混合A（163406）、平安医 疗健康混合A（003032）退出十大流通股东之列。 资料显示，诺诚健华医药有限公司位于北京市昌平区中关村生命科学园生命园路8号院8号楼，成立日期 2015年11月3日，上市日期2022年9月21日，公司主营业务涉及诺诚健华医药有限公司是一家主要从事生 物医药的研发、生产和商业化的中国公司。该公 ...

Company Overview - Shenzhen Xinlitai Pharmaceutical Co., Ltd. was established on November 3, 1998, and listed on September 10, 2009. The company is located at 37th Floor, Green View Plaza, Chegongmiao, Shenzhen, Guangdong Province. Its main business involves the research, production, and sales of pharmaceuticals and medical devices [1][2]. Financial Performance - For the first half of 2025, Xinlitai achieved operating revenue of 2.131 billion yuan, representing a year-on-year growth of 4.32%. The net profit attributable to shareholders was 365 million yuan, with a year-on-year increase of 6.10% [2]. - Since its A-share listing, Xinlitai has distributed a total of 7.204 billion yuan in dividends, with 1.649 billion yuan distributed over the past three years [3]. Stock Performance - As of September 23, Xinlitai's stock price was 50.84 yuan per share, with a market capitalization of 56.677 billion yuan. The stock has increased by 67.07% year-to-date, but has seen a decline of 3.58% over the past five trading days and 4.24% over the past 20 days [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on June 17, where it recorded a net buy of -41.9885 million yuan [1]. Shareholder Structure - As of June 30, 2025, Xinlitai had 24,000 shareholders, a decrease of 0.79% from the previous period. The average number of circulating shares per shareholder was 46,403, an increase of 0.80% [2]. - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with significant changes in their holdings [3].

资金流向方面，主力资金净流出1306.31万元，特大单买入320.35万元，占比2.81%，卖出1083.71万元， 占比9.52%；大单买入3012.48万元，占比26.46%，卖出3555.44万元，占比31.23%。 泰恩康今年以来股价涨128.79%，近5个交易日跌12.42%，近20日跌1.51%，近60日跌7.64%。 9月23日，泰恩康盘中下跌2.03%，截至11:14，报33.84元/股，成交1.14亿元，换手率1.09%，总市值 143.99亿元。 截至6月30日，泰恩康股东户数1.09万，较上期减少33.05%；人均流通股27747股，较上期增加49.36%。 2025年1月-6月，泰恩康实现营业收入3.47亿元，同比减少12.23%；归母净利润3708.48万元，同比减少 56.75%。 资料显示，广东泰恩康医药股份有限公司位于广东省汕头市龙湖区泰山北路万吉南二街8号A幢，成立 日期1999年1月22日，上市日期2022年3月29日，公司主营业务涉及代理运营及研发、生产、销售医药产 品、医疗器械、卫生材料并提供医药技术服务与技术转让等。主营业务收入构成为：医药代理 65.16%，医药制造 ...

Company Overview - China Resources Double Crane Pharmaceutical Co., Ltd. is located in Beijing and was established on May 16, 1997, with its listing date on May 22, 1997. The company is primarily engaged in the development, manufacturing, and sales of pharmaceuticals [1]. Financial Performance - For the first half of 2025, the company reported operating revenue of 5.742 billion yuan, a year-on-year decrease of 3.16%, and a net profit attributable to shareholders of 975 million yuan, down 6.79% year-on-year [2]. - The company has cumulatively distributed 4.356 billion yuan in dividends since its A-share listing, with 1.057 billion yuan distributed over the past three years [3]. Stock Performance - As of September 23, the stock price of China Resources Double Crane fell by 2.01%, trading at 18.52 yuan per share, with a total market capitalization of 19.238 billion yuan. The stock has decreased by 4.68% year-to-date and by 2.83% over the last five trading days [1]. - The stock's trading volume showed a net outflow of 17.2454 million yuan from main funds, with significant selling pressure observed [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased to 57,400, a reduction of 2.78%. The average circulating shares per person increased by 3.41% to 17,980 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 12.2414 million shares, an increase of 550,200 shares compared to the previous period [3].

Company Overview - Sichuan Kelun Pharmaceutical Co., Ltd. is located in Chengdu, Sichuan Province, and was established on May 29, 2002. The company was listed on June 3, 2010. Its main business involves the development, production, and sales of large-volume infusion products. The revenue composition is as follows: non-infusion products 48.37%, infusion products 41.28%, R&D projects 7.01%, and others 3.33% [1]. Financial Performance - For the first half of 2025, Kelun Pharmaceutical achieved operating revenue of 9.083 billion yuan, a year-on-year decrease of 23.20%. The net profit attributable to the parent company was 1.001 billion yuan, down 44.41% year-on-year [2]. - Since its A-share listing, Kelun Pharmaceutical has distributed a total of 6.697 billion yuan in dividends, with 3.386 billion yuan distributed in the last three years [3]. Stock Market Activity - As of September 23, Kelun Pharmaceutical's stock price was 36.54 yuan per share, with a market capitalization of 58.393 billion yuan. The stock has increased by 24.16% year-to-date, but has seen a decline of 0.90% over the last five trading days and 4.35% over the last 20 days [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on April 30, where it recorded a net purchase of 31.8792 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for Kelun Pharmaceutical was 34,200, an increase of 2.55% from the previous period. The average circulating shares per person were 38,138, a decrease of 2.49% [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by China Europe Medical Health Mixed A and a decrease in holdings by Hong Kong Central Clearing Limited [3].

Core Viewpoint - The stock of Ailis has experienced a significant increase of 78.14% year-to-date, despite a recent decline of 2.02% on September 23, 2023, indicating volatility in the market [1]. Financial Performance - For the first half of 2025, Ailis reported a revenue of 2.374 billion yuan, representing a year-on-year growth of 50.57% [2]. - The net profit attributable to shareholders for the same period was 1.051 billion yuan, showing a year-on-year increase of 60.22% [2]. Shareholder Information - As of June 30, 2025, Ailis had 13,000 shareholders, an increase of 3.61% from the previous period [2]. - The average number of circulating shares per shareholder was 34,578, which decreased by 3.48% compared to the previous period [2]. Dividend Distribution - Ailis has distributed a total of 653 million yuan in dividends since its A-share listing [3]. Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included notable entities such as Huaxia SSE Sci-Tech Innovation Board 50 ETF, which increased its holdings by 1.3199 million shares to 12.4209 million shares [3]. - Hong Kong Central Clearing Limited reduced its holdings by 2.4609 million shares to 10.3778 million shares [3]. - New institutional shareholder, China Europe Medical Health Mixed A, entered the top ten with a holding of 9.1525 million shares [3].

Company Overview - Dongcheng Pharmaceutical Co., Ltd. is located in Yantai Economic and Technological Development Zone, Shandong Province, and was established on December 31, 1998. The company was listed on May 25, 2012 [2] - The main business involves the research, production, and sales of heparin sodium raw materials and chondroitin sulfate. The revenue composition is as follows: raw materials related products 44.16%, nuclear medicine products 36.38%, formulation products 13.17%, and others 6.30% [2] Stock Performance - As of September 23, the stock price of Dongcheng Pharmaceutical decreased by 2.08%, trading at 15.10 CNY per share, with a total market capitalization of 12.451 billion CNY [1] - Year-to-date, the stock price has increased by 23.87%, but it has seen a decline of 5.21% over the last five trading days and 13.76% over the last 20 days [2] Financial Performance - For the first half of 2025, Dongcheng Pharmaceutical reported a revenue of 1.384 billion CNY, a year-on-year decrease of 2.60%. The net profit attributable to shareholders was 88.6525 million CNY, down 20.70% year-on-year [2] - The company has distributed a total of 1 billion CNY in dividends since its A-share listing, with 293 million CNY distributed over the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders increased to 23,600, up 9.19% from the previous period. The average circulating shares per person decreased by 8.42% to 31,554 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 12.4202 million shares, an increase of 511,700 shares compared to the previous period [3] Market Activity - The net outflow of main funds was 2.1999 million CNY, with large orders accounting for 12.55% of purchases and 14.75% of sales [1]